- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 802 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 32
- States / cities
- Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 26
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma
- Interventions
- PCV20
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,840 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
- Biological
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 45
- States / cities
- Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
- Conditions
- Infections, Meningococcal
- Interventions
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31-valent pneumococcal conjugate vaccine, PCV20
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 30
- States / cities
- Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PCV20
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,663 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
- Conditions
- Vaccine, Pneumococcal Disease
- Interventions
- Pneumococcal Vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- HIV Infections, Age
- Interventions
- Conjugate Pneumococcal Vaccine 20 (PCV20)
- Biological
- Lead sponsor
- Hennepin Healthcare Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Community-Acquired Pneumonia (CAP)
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 22,234,435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Hollywood, Florida + 22 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 835 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more
- Conditions
- Alpha 1-Antitrypsin, COPD, Antibody Deficiency
- Interventions
- 20-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
- Biological
- Lead sponsor
- Seema Bhat
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
- Conditions
- Chickenpox
- Interventions
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 911 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Interventions
- AFX3772, Prevnar 13, Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 388 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 42
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
- Conditions
- Pneumococcal Infection
- Interventions
- V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2)
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Months to 15 Months
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Madera, California • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Spirometry
- Interventions
- Community health worker-delivered multi-component respiratory health intervention
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 9 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pneumococcal Vaccines
- Interventions
- 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • DeLand, Florida • Hollywood, Florida + 17 more
- Conditions
- Community-Acquired Pneumonia (CAP)
- Interventions
- Receipt of PCV20
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 846,279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma
- Interventions
- AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
- Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland